Resources Resources
AkebiaCares Enrollment Form (English/Spanish)

Download and fill out this form to get access to a dedicated case manager

Download PDF (English) Download PDF (Spanish)
AkebiaCares Enrollment Form Tips

Helpful tips to consider when filling out the AkebiaCares Enrollment Form

Download PDF
Patient-friendly Guide on How to Apply for Extra Help/Low Income Subsidy (LIS) Guide (English/Spanish)

An easy-to-follow guide for patients who need Extra Help/LIS through Medicare Part D

Download PDF (English) Download PDF (Spanish)
Commercial Copay Coupon

Eligible patients with commercial insurance can pay as little as $0 for AURYXIA

Download PDF
Prior Authorizations (PA) Tips/Guidelines

What to know when submitting a Prior Authorization

Download PDF
Appeal Letter Tips and Template

Helpful tips to write and submit an Appeal Letter

Download PDF
Insurance Access Flashcard for Patients with Hyperphosphatemia

Learn more about coverage options for your patients with Medicare or commercial insurance

Download PDF
Insurance Access Flashcard for Patients with Iron Deficiency Anemia

Learn more about coverage options for your patients with commercial insurance

Download PDF
Does Your Patient Qualify for Additional Financial Assistance From Medicare?

Review the current Federal Poverty Level guidelines to determine if your patient’s household size and income may qualify them for Extra Help/LIS

Download PDF


AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
  • The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis



AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis


  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children


The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)
  • Iron Deficiency Anemia in CKD Not on Dialysis: Discolored feces (22%), diarrhea (21%), constipation (18%), nausea (10%), abdominal pain (5%) and hyperkalemia (5%)


  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information